TITLE

It seems as if my doctor and I have tried just about everything for my chronic constipation. Is there anything new that might be of help?

PUB. DATE
November 2011
SOURCE
Mayo Clinic Health Letter;Nov2011, Vol. 29 Issue 11, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article answers a question about the management and treatment of chronic constipation.
ACCESSION #
66654208

 

Related Articles

  • Amitiza.  // Formulary;Mar2006, Vol. 41 Issue 3, p111 

    The article talks about lubiprostone as a channel activator for chronic constipation. It was approved on January 31, 2006, for the treatment of chronic idiopathic constipation (CIC) in adults. Lubiprostone helps in alleviating symptoms associated with constipation. A study was conducted to...

  • Focus on… Lubiprostone: A novel chloride channel activator for the treatment of constipation. Orr, Katherine Kelly // Formulary;Mar2006, Vol. 41 Issue 3, p118 

    Lubiprostone (Amitiza, Sucampo/Takeda) was approved on January 31, 2006, for the treatment of chronic idiopathic constipation in adults when the cause of the condition is unknown. The agent has a unique mechanism of action compared with current therapies on the market in that it locally...

  • Amitiza Approved for OIC.  // Monthly Prescribing Reference;May2013, Vol. 29 Issue 5, pA-26 

    The article informs that the lubiprostone capsules Amitiza has been approved for the treatment of opioid-induced constipation (OIC) in adults who are suffering with chronic non-cancer pain.

  • Process of elimination. Deas, Gerald W. // New York Amsterdam News;4/20/96, Vol. 87 Issue 16, p14 

    Reports on the mental and physical restraint of bowl movement, a common cause of constipation. When the feeling of excretion may return; Physical symptoms of suppressed bowl movement; Slugglishness; Abdominal bloating; Headache; Affects of chronic constipation; How persons who spend more than...

  • Pegasys antiviral approved.  // AIDS Alert;12/1/2011, p142 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the use of disposable autoinjector (DAI) in administering peginterferon alfa-2a (Pegasys�), the antiviral for chronic hepatitis C (CHC) treatment.

  • FDA Actions. Elliott, William T. // Primary Care Reports;Sep2007, Vol. 13 Issue 9, p2 

    The article offers news briefs related to drug approval in the U.S. The Oncologic Drugs Advisory Committee of the U.S. Food & Drug Administration (FDA) has recommended the approval of raloxifene for the indication of breast cancer prevention in high risk women. The FDA has approved restricted...

  • Naloxegol approved for opioid-induced constipation.  // Reactions Weekly;Oct2014, Vol. 1521 Issue 1, p3 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved use of Movantik naloxegol for the treatment of opioid-induced constipation with Chronic non-cancer pain in adult patients.

  • CONSTIPATION TREATED BY CBT AND HYPNOSIS. Fenton, Karla // Australian Journal of Clinical & Experimental Hypnosis;May2011, Vol. 39 Issue 1, p128 

    The article discusses the use of cognitive behavioral therapy (CBT) and hypnosis to treat constipation. It says that hypnosis facilitates quicker and lasting effect on the therapies. According to the author, constipation is a common condition that is seldom discussed with the doctor beyond the...

  • New drugs raise HCV cure rate.  // Hospital Employee Health;Jan2012, Vol. 31 Issue 1, p7 

    The article discusses the approval of Victrelis by Merck and Incivek by Vertex, for the treatment of hepatitis C virus (HCV) infection. It mentions that the drugs boost the effectiveness of interferon and ribavirin by blocking the virus's ability to replicate. Douglas Dieterich, a professor of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics